Beat The Denominator

Investors should view the recent 10% price drop in Hims & Hers Health (HIMS) as a high-conviction "buy the dip" opportunity caused by a market misunderstanding of their new debt structure. The company secured $350 million in capital at a 0% interest rate, providing free funding to scale their AI MedMatch technology and international expansion through the Eucalyptus acquisition. This acquisition alone is expected to boost annual recurring revenue by up to $500M, yet the stock remains undervalued relative to its 32% projected growth rate. Institutional confidence is anchored by a conversion price of $29.53, suggesting professional investors expect significant upside from current levels through 2032. This is a long-term core holding for those betting on AI-driven healthcare and the company's transition into a high-margin global platform.

Investors should consider Zoom Video Communications (ZM) as a high-conviction "value play" to gain indirect exposure to the private AI giant Anthropic. Zoom holds an estimated 1.2% stake in Anthropic, which at a projected $900 billion valuation would be worth over $10 billion, or roughly 37% of Zoom’s current market cap. By subtracting Zoom's $7 billion in cash and the value of this AI stake, investors are essentially buying the core, profitable software business at a steep discount. This setup provides a significant "margin of safety" compared to overextended hardware stocks, with a major catalyst expected during a potential Anthropic IPO in late 2025 or 2026. For those seeking diversified AI exposure, Alphabet (GOOGL) also serves as a secondary proxy for Anthropic’s growth alongside Zoom.

Investors should consider MicroStrategy (MSTR) as it aggressively accelerates its Bitcoin (BTC) accumulation, significantly outperforming analyst expectations for capital issuance and yield. The stock is currently viewed as undervalued relative to its underlying assets, with a technical price target of $100 expected within the next one to two weeks. For direct crypto exposure, Bitcoin is currently preferred over AI stocks, which are viewed as overheated and overextended in the short term. Use weekend volatility and geopolitical sell-offs as strategic entry points for BTC, as it remains the primary liquid outlet for macro anxiety. Monitor MSTR's recovery speed following share issuances as a key indicator of shareholder conviction and upward momentum.

Maintain a core "insurance" position of 5% to 10% of your portfolio in Bitcoin (BTC) held in cold storage to protect against systemic financial collapse. For aggressive growth, use MicroStrategy (MSTR) as a high-beta proxy to gain leveraged exposure to BTC price movements through the traditional stock market. Diversify into "public computer networks" by taking venture-style positions in Solana (SOL) and Sui (SUI), which are positioned to disrupt traditional finance and social media sectors. Investors seeking high yields should explore DeFi protocols and BTC-backed stablecoins, though you should expect current promotional yields of 50% to normalize toward 20% over time. Monitor the 10 to 20-year transition from traditional companies to decentralized protocols as regulatory clarity improves for the broader digital asset ecosystem.

Investors should consider Nubank (NU) a high-conviction buy following its recent dip to the $12 range, as its 7.8x EBITDA multiple significantly undervalues its 31% revenue growth and expansion into Mexico. Klarna (KLAR) offers a massive valuation play at just 0.5x forward revenue, with an expected shift to EPS profitability in Q2 or Q3 serving as a major upcoming catalyst. While Sezzle (SEZL) is performing well and building user loyalty, it is currently a less attractive entry point than its peers after a 50% price recovery from March lows. For those looking at the infrastructure behind these lenders, Pagaya (PGY) is highlighted as an undervalued AI-driven credit partner trading at a deep discount. This broader Fintech sector currently provides a rare "bargain" opportunity as capital rotates away from overextended AI stocks and back toward high-growth digital banking.

Investors should consider MicroStrategy (MSTR) as management aggressively retires convertible debt at a discount, a move that prevents future shareholder dilution and signals high conviction that the stock will trade well above $672 by 2029. Focus on the MSTR 2030B tranche of convertible notes as the next likely target for buybacks, offering an accretive opportunity as the company optimizes its balance sheet. While STRC preferred shares are becoming fundamentally safer due to an improving "BTC Rating," the low 1.5%–2% arbitrage yield makes them more suitable for institutional hedging than retail portfolios. Maintain a long-term horizon for Bitcoin (BTC) through the end of the decade, as it remains a volatile "risk asset" highly sensitive to Federal Reserve interest rate policy and macro uncertainty. Avoid the Real Estate sector and mortgage-related businesses for now, as high interest rates and bond market volatility continue to pressure these industries.

Investors should closely monitor STRC, which is seeing record-breaking inflows of nearly $1 billion and is projected to acquire 21,000 Bitcoins weekly. To avoid "irrational exuberance" and potential price cooling, retail investors should be cautious of buying STRC immediately before its monthly ex-dividend date when demand typically peaks. For a more stable yield experience with reduced volatility, consider SEDA, which utilizes a daily dividend payout structure to eliminate the monthly "pump and dump" cycles seen in traditional funds. Keep a close watch on MSTR (MicroStrategy) to ensure it maintains its 1.5x beta to Bitcoin; a drop in this correlation may signal that capital is rotating into newer yield-bearing instruments. Watch for upcoming 8-K filings from Michael Saylor, as MSTR is expected to launch new competitive instruments to counter the daily-dividend model introduced by rivals.

Investors should closely monitor Asset Entities Inc. (ASST) as it launches a disruptive daily dividend structure for its SEDA product, aiming to eliminate price volatility caused by traditional monthly arbitrage. This regulatory breakthrough puts immediate competitive pressure on MicroStrategy (MSTR), which may be forced to pivot its STRC strategy toward a daily payout model to maintain its market lead. For those seeking low-volatility income, ASST offers a first-of-its-kind consistent yield, though investors must watch for any NASDAQ regulatory pushback regarding their aggressive dividend declaration schedule. Meanwhile, MSTR remains a high-conviction play for Bitcoin accumulation, recently demonstrating massive capital inflows through its At-The-Market (ATM) offering. The overarching opportunity lies in the "Digital Credit" sector, where shifting to daily payouts is expected to stabilize asset prices and provide a more reliable entry point for long-term holders.

Investors should prepare for a short-term sell-off in MicroStrategy (MSTR) following the upcoming ex-dividend date this Friday, viewing any price drop as a recovery play for the following weeks. Bitcoin (BTC) remains a high-conviction buy as MSTR scales its capital raises toward a potential $1 billion per week in purchase volume, creating massive institutional buy-side pressure. The shift in Federal Reserve leadership toward a more dovish stance is a major macro catalyst for scarce risk assets, suggesting that current "undervalued" prices are a consolidation phase before a rally. Traders can exploit the "Stretch" strategy by monitoring MSTR's twice-monthly at-the-market offerings, which provide the financial engineering to capture yield for common shareholders. Long-term investors should hold through current volatility, as the necessity for lower interest rates to manage national debt acts as a structural tailwind for the entire crypto sector.

Investors should exercise extreme caution with Nebius Group (NBIS) following its 700% rally, as the current "casino-like" price action suggests the stock has decoupled from its fundamentals. While the company remains fundamentally strong with a massive 1.2 gigawatt AI site expansion, a looming capital raise to fund infrastructure could trigger a price correction or share dilution. Existing shareholders should consider trimming positions or selling if the parabolic move continues, especially as the stock becomes an uncomfortably large portion of a portfolio. For those seeking better relative value, Hims & Hers Health (HIMS) presents a potential opportunity, as the stock recently dropped 20% despite raising financial guidance. Overall, the AI Infrastructure sector remains highly volatile, and investors should wait for cooling-off periods rather than chasing violent "catch-up" rallies.

Investors should monitor MicroStrategy (MSTR) for a massive capital injection, as the company is expected to raise up to $1 billion via its STRC digital credit instrument by the end of this week. This capital is anticipated to flow directly into Bitcoin (BTC), providing a significant demand pillar and price support despite recent macro volatility and high CPI data. Expect heightened volatility through Thursday, as the day before the "ex-dividend" date for these instruments historically triggers wild price action. Traders should look for an official announcement next Monday regarding the total amount of Bitcoin purchased, which could serve as a major market catalyst. While BTC has recently dipped below $80,000, the success of these "Bitcoin-backed" financial products suggests a resilient new sector for institutional liquidity.

XPeng (XPEV) is the top high-conviction pick in the sector, offering a potential 10x return as it trades 85% below its highs despite reaching a cash-flow positive inflection point. With 47% projected revenue growth and a dominant position in self-driving tech and robotics, XPEV is the most attractive "pure-play" EV growth trade available via U.S. brokers. Investors seeking a deep-value alternative should consider NIO, which trades at a low 0.1x forward revenue multiple, though its heavy investment in battery-swapping infrastructure adds strategic risk. Avoid BYD (BYDDF) due to its slower growth, OTC trading hurdles, and lack of margin availability for retail accounts. For broader exposure, treat Tesla (TSLA) as a long-term play on AI and Robotics rather than a direct bet on the EV adoption cycle, which is now primarily a battle between Tesla and Chinese manufacturers.

The recent 13% price drop in Hims & Hers Health (HIMS) presents a high-conviction buying opportunity, as the sell-off over a one-time $28 million write-off ignores strong fundamental growth. The company is seeing massive momentum in the weight-loss sector, recording 125,000 Wegovy shipments in just six weeks and generating high-margin recurring revenue through a $149/month prescription fee. Investors should look toward 2026 growth, which is expected to hit the high 30% range—outperforming management’s conservative guidance—driven by the upcoming Eucalyptus acquisition and international expansion. HIMS is successfully transitioning into a major distribution partner for big pharma and diagnostic testing, backed by a stock buyback program that provides a valuation floor. Capitalize on this "cash pay" healthcare leader as it integrates AI medical agents and proprietary data to scale its personalized medicine platform globally.

Investors should consider Hims & Hers Health (HIMS) as a high-growth opportunity following its raised 2026 revenue guidance of up to $3 billion, a target that likely "sandbags" the impact of its upcoming Eucalyptus acquisition. The company is aggressively scaling its international footprint and weight loss category, leveraging strategic partnerships with Eli Lilly (LLY) and Novo Nordisk (NVO) to offer branded GLP-1 medications. A key entry point for new patients is Hims Labs, which uses low-cost diagnostic testing to funnel users into high-margin subscription treatments for testosterone and weight loss. While the stock is prone to high volatility, its current valuation appears attractive relative to a projected 30% growth rate and its expansion into AI-driven diagnostics. Long-term investors should monitor the adoption of next-generation drugs like Retatrutide and the company’s transition toward a data-driven "AI doctor" model.

Investors should consider TransMedics Group (TMDX) as a high-conviction buy following its 50% price drop to the $60s, as the company maintains a strong 25% growth target and a path to 10,000 transplants by 2028. Celsius Holdings (CELH) offers a deep-value opportunity near $29 with an attractive EV/GP/RG of 0.13, especially as it neutralizes competition through the Alani acquisition and expands internationally. Hims & Hers Health (HIMS) is currently undervalued at $30, with significant upside potential from the Eucalyptus acquisition and the rollout of branded GLP-1 weight loss medications. Focus on these "brutalized" growth stocks where temporary margin pressures or minor earnings misses have created entry points at significant discounts to their historical valuations. Avoid short-term options volatility around earnings and instead build positions in these names to capture long-term market share gains in medical innovation and specialized consumer goods.

Investors should monitor MicroStrategy (MSTR) for increased share issuance and Bitcoin buying if its Market Net Asset Value (MNAV) climbs back into the 1.6x to 1.7x range. STRC presents a time-sensitive opportunity as it recovers to "Par" value, with a critical ex-dividend date occurring this Friday. Despite recent volatility and retail-driven sentiment shifts, STRC is on track for a significant $1 billion issuance week, signaling robust demand for the derivative. Bitcoin (BTC) is currently in a healthy consolidation phase between $80,800 and $82,000, offering a potential entry point for long-term bulls while the Fear and Greed Index remains neutral. While defensive sectors like Biotech (PFE) are being discussed, the primary actionable trend remains the "Digital Credit Takeover" through Bitcoin-backed equities.

Palantir (PLTR) is a high-conviction "catch-up" trade, as its stellar 80%+ revenue growth in the U.S. commercial and government sectors suggests it is overdue for a rally compared to hardware peers. Despite its reputation, PLTR is considered mathematically cheap at current levels and serves as a core "N-of-1" software play for those looking beyond the hardware boom. NVIDIA (NVDA) remains a top-tier conviction buy, described as "super cheap" and undervalued with a valuation metric of 0.61 ahead of its next growth phase. While Micron (MU) has already seen a parabolic move, it remains surprisingly inexpensive at a 0.28 valuation metric, though investors should be mindful of its historical cyclicality. Avoid chasing the recent parabolic surge in AMD, and instead focus on the rotation into "load-bearing" AI infrastructure like PLTR and NVDA that provides essential sovereign and institutional software.

Investors seeking high-yield income should prioritize STRC, which is transitioning to a twice-monthly dividend schedule potentially starting in July. Bitcoin (BTC) is currently viewed as a "value" play at the $81,000 level, offering a favorable entry point before a projected move toward the $126,000 range. While MicroStrategy (MSTR) may sell Bitcoin at a loss for strategic tax-loss harvesting, investors should view these "bad headlines" as tactical moves rather than a loss of conviction. Management considers MSTR common stock undervalued at current Net Asset Value multiples, suggesting long-term upside as the company rebrands into an AI-focused entity via its Mosaic platform. Monitor the company's integration with Snowflake (SNOW), as this neutral software layer is designed to drive the next phase of institutional adoption.

Investors should consider Oscar Health (OSCAR) as a high-conviction growth play, given its massive 53% year-over-year revenue growth and a valuation that remains "dirt cheap" relative to its peers. The company is aggressively targeting the gig economy and employer-sponsored ICHRAs, positioning it to capture a more profitable and less regulated segment of the healthcare market. Management’s conservative Medical Loss Ratio (MLR) guidance of 83% suggests a high likelihood of future earnings beats if they maintain their current operational efficiency. OSCAR is also leveraging AI agents to structurally lower costs and improve margins, a technological edge that traditional insurers like UnitedHealth Group (UNH) may struggle to replicate quickly. With a target of $19 billion in revenue by 2026, this stock offers a significant contrarian opportunity for those looking to diversify into high-growth healthcare.

Investors should treat MicroStrategy (MSTR) as a high-volatility, high-yield savings product designed to capture Bitcoin (BTC) growth through aggressive at-the-market equity offerings. For those with a lower risk tolerance, STRC serves as a lower-volatility alternative to preserve purchasing power against fiat devaluation. Monitor the upcoming "ex-dividend" date this Friday, as it is expected to be a significant catalyst for trading volume and price volatility. Bitcoin remains the primary long-term hold with a multi-decadal horizon, acting as a mathematical hedge against a weakening US Dollar and a target of $30 million per coin. Avoid traditional fixed-income assets in favor of these "hard money" instruments to capture a natural yield that far exceeds manipulated government interest rates.